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Dynamic transmission modelBackground: To inform national healthcare authorities whether quadrivalent influenza vaccines (QIVs)
provide better value for money than trivalent influenza vaccines (TIVs), we assessed the cost-
effectiveness of TIV and QIV in low-and-middle income communities based in South Africa and
Vietnam and contrasted these findings with those from a high-income community in Australia.
Methods: Individual based dynamic simulation models were interfaced with a health economic analysis
model to estimate the cost-effectiveness of vaccinating 15% of the population with QIV or TIV in each
community over the period 2003–2013. Vaccination was prioritized for HIV-infected individuals, before
elderly aged 65+ years and young children. Country or region-specific data on influenza-strain circula-
tion, clinical outcomes and costs were obtained from published sources. The societal perspective was
used and outcomes were expressed in International$ (I$) per quality-adjusted life-year (QALY) gained.
Results: When compared with TIV, we found that QIV would provide a greater reduction in influenza-
related morbidity in communities in South Africa and Vietnam as compared with Australia. The incre-
mental cost-effectiveness ratio of QIV versus TIV was estimated at I$4183/QALY in South Africa, I
$1505/QALY in Vietnam and I$80,966/QALY in Australia.
Conclusions: The cost-effectiveness of QIV varied between communities due to differences in influenza
epidemiology, comorbidities, and unit costs. Whether TIV or QIV is the most cost-effective alternative
heavily depends on influenza B burden among subpopulations targeted for vaccination in addition to
country-specific willingness-to-pay thresholds and budgetary impact.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Seasonal influenza has been estimated to cause between 3 and
5 million cases of severe illness and 250,000–500,000 deaths glob-
ally each year [1]. The elderly, very young children and people with
specific health conditions are at highest risk of developing serious
complications [2]. In addition, influenza imposes a significant eco-
nomic burden involving health care costs and productivity losses.
In low- and middle-income countries (LMICs), costs due to sea-
sonal influenza may have a considerable economic impact, esti-
mated at 2–6% of gross domestic product (GDP) per capita,
998 P.T. de Boer et al. / Vaccine 36 (2018) 997–1007compared to only 0.04–0.13% of GDP per capita in high income
countries [3].
Annual vaccination is currently the most effective way of pre-
venting influenza disease [1]. The commonly used trivalent influ-
enza vaccines (TIVs) contain strains of two influenza A sub-types
(H1N1 and H3N2) and one influenza B lineage (either Victoria or
Yamagata), based on recommendations from the World Health
Organization (WHO). Over the last decade, vaccine protection
was regarded as sub-optimal in some years due to mismatches
with the dominant circulating B lineage, or due to co-circulation
of both B lineages in the same season [4]. In a response to this,
quadrivalent influenza vaccines (QIVs) have been developed con-
taining both B lineages (Victoria and Yamagata).
Previous cost-effectiveness analyses on influenza vaccination
have had a focus on high-income countries with few economic
studies of influenza vaccination in LMICs [3,5–7]. For instance, in
a recent paper QIV was found to be cost-effective in the United
States [8]. Some LMICs are now considering whether seasonal
influenza vaccination should be introduced in their vaccination
programs and whether this should involve TIVs or QIVs. Signifi-
cantly, cost-effectiveness outcomes are not directly transferrable
between countries, due to differences in circulating strains, demo-
graphics, climate, co-morbidities, health care infrastructure and
budgets. For example, a study in South Africa, a country with con-
siderable human immunodeficiency virus (HIV) prevalence, esti-
mated that the incidence of influenza-associated severe lower
respiratory tract infections was 4–8 times higher in HIV-infected
individuals as compared with HIV-uninfected individuals [9].
In this study we analyzed the cost-effectiveness of influenza
vaccination with TIV and QIV in three communities: Agincourt, a
low-income rural community in South Africa; Thai Nguyen, a
middle-income urban community in Vietnam; and Albany, a
high-income urban/rural community in Australia. For this purpose,
individual based simulation (IBS) models for each of the three com-
munities were developed and interfaced with a health economic
analysis model, capturing the specific demographics and health
profiles of each community. As circulation of the different influ-
enza B lineages and corresponding TIV vaccine matches are hard
to predict, we studied the impact of TIV and QIV using retrospec-
tive data, over the period 2003–2013 (11 seasons).2. Methods
2.1. Model overview
An overview of the analytic methodology used in this study is
shown in Fig. 1; parenthesized numbers below refer to numbered
items in the figure. Population and geographic data was used to
build models for communities in South Africa, Vietnam and Aus-
tralia (1). For each country, influenza strain circulation data was
used to calibrate strain-specific influenza transmission parameters
for the years 2003–2013 (2). For each of these combinations of
communities and study years (39 in total), 3 different vaccination
strategies were created: no vaccination, vaccination with TIV
(using the actual influenza B strain present in the vaccine used in
that country in that year), and vaccination with QIV (using both
influenza B lineages) (3). For each combination of community, year
and vaccination strategy (in total 117 scenarios) established indi-
vidual based influenza spread simulation models (4) were used
to assess the incidence of symptomatic influenza, stratified by
age and HIV status (5). Influenza spread simulations also generated
counts of work-days lost due to influenza (6).
These outputs, along with community, age, and HIV status-
specific risk parameters (7) served as input to a health outcomes
model (8), which generated numbers of clinical visits, hospitaliza-tions and deaths due to influenza (9). Using cost and quality of life
parameters (10), an economic analysis process (11) subsequently
took the health outcomes counts, work-days lost and generated
total costs and quality-adjusted life year (QALY) losses for each
scenario. The differences between corresponding no-vaccination
and vaccination scenarios served to calculate incremental cost-
effectiveness ratios (ICERs) for the TIV and QIV vaccination strate-
gies. Sensitivity analyses were performed to assess the robustness
of results due to uncertainty in health outcome parameters, cost
parameters and the stochastic nature of influenza spread.
2.2. Individual based simulation models
2.2.1. Community models
The main characteristics of each community are shown in
Table 1. Agincourt represents a low-income rural area in northern
South Africa, with HIV prevalence at 16% in the adult population
and a relatively low life-expectancy. The lower-middle income
community of Thai Nguyen is located in north Vietnam near Hanoi
and represents an urban setting and a relatively low HIV preva-
lence in adults (2.3%). Albany reflects a combined urban and rural
community in Western Australia, representative of high-income
countries with high life-expectancy and low HIV prevalence
(0.2%). Current seasonal influenza vaccination coverage is moder-
ate in Albany (20%), negligible in Agincourt (<2%) and absent in
Thai Nguyen.
Each model was constructed using community-specific census
and health data, and represents a community of individuals, each
labelled with age (in bands 0–5, 6–12, 13–17, 18–24, 25–44, 45–
64, 65+ years) and HIV status (see supplementary methods
Table S1 for more details). Census and local government data
was used to assign each individual to a number of contact groups
(i.e. groups which the individual meets daily, including house-
holds, school classes, or groups of work colleagues). The size and
overlapping memberships of contact groups is a key determinant
of influenza spread, and these groups were constructed taking into
account community-specific details including employment rate,
workplace size, school attendance, number and size of schools,
and household sizes. The IBS community models of Agincourt
and Albany have been described in more detail previously
[10,11]. The community model of Thai Nguyen in Vietnam was
developed using the same methodology as the other models and
is described in detail in the supplementary material.
2.2.2. Influenza transmission
As the simulation software runs, individuals come into daily
contact with other individuals in their contact groups, where influ-
enza transmission from infectious to susceptible individuals may
occur: a stochastic choice determines if transmission fails, or
results in symptomatic or asymptomatic infection. The model is
able to capture the infection history of each individual regarding
infection status, i.e. susceptible, infected, infectious or immune
(due to infection or vaccination). Separate infectivity status was
recorded of each of the four seasonal influenza strains A(H3N2),
A(H1N1), B Yamagata, and B Victoria. The output of the IBS-
model consisted of the number of symptomatic influenza cases
and number of work days lost. A work-day lost was deemed to
have occurred when an individual who would have otherwise
attended a workplace withdrew to their household, either due to
influenza infection themselves, or because one or more children
in the household was ill with influenza. Main input parameters
of the IBS-model are listed in the supplementary methods
Table S2. The annual attack rate of influenza infection in each
unvaccinated community was set at 21% and annual symptomatic
attack rate (SAR) at 5% [12,13]. However, as the SAR of 5% has been
determined in a setting where seasonal influenza vaccination
Table 1
Main characteristics of the communities studied in this analysis.
South Africa Vietnam Australia
Community Agincourt Thai Nguyen Albany
Community size 40,400 74,000 29,400
Setting Rural Urban, with large student population Combined rural and urban
GDP/capita I$1000 I$5000 I$42,500
Life-expectancy [45–47] 60.1 76.2 82.4
HIV prevalence in adults [66–69] 16% 2.3% 0.2%
Vaccination coverage [70,71] 2% 0% 20%
Fig. 1. Overview of the interfaced individual based simulation model and the health economic model. HIV: Human Immunodeficiency Virus; QALY: Quality-Adjusted Life
Year. The numbers refer to the textual methodology overview given at the beginning of the Methods section.
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The transmissibility of each strain in each simulation year was cal-
ibrated to match the proportion of each strain occurring that year
for each community (Fig. 2) [14–17]. As no information on the lin-
eages of influenza B infections was available for Vietnam, influenza
B lineage data from Thailand was used to partition the Vietnamese
B infection between the two lineages [18]. A more detailed descrip-
tion of the transmission parameter calibration process is given in
the supplementary material.
2.2.3. Vaccination
The number of vaccine doses used each year was assumed at
15% of the population and prioritized to vulnerable sub-groups:
first to HIV-infected individuals, then to elderly aged 65+ years,
and the remaining to children aged <5 years. Age-specific cover-
ages are shown in supplementary methods Table S3. In the Agin-
court and Albany communities, the Southern Hemisphere TIV
vaccine composition as used in Australia and South Africa was
assumed (Supplementary methods Table S4) [19]. In the case of
VN, where currently no seasonal influenza vaccination occurs,
the TIV recommendation for the previous northern hemisphere
winter was used [19]. Vaccine efficacy was set at 65% for individu-
als aged <65 years and at 55% in people aged 65 and older [20–22].
No cross-strain vaccine protection was assumed; that is, vaccina-
tion with TIV did not provide any protection against the influenza
B strain not included in the vaccine and vaccine efficacy for that
strain was zero.
2.3. Health outcomes model
Using the age and HIV-specific counts of symptomatic cases
generated by the IBS model, counts of clinical visits, hospitaliza-
tions and deaths were generated using age- and country-specificprobabilities for each community and vaccination strategy (Sup-
plementary methods Table S5). We explicitly applied higher risks
of clinical events for HIV-infected individuals with influenza dis-
ease as compared with non-HIV-infected individuals [9,23]. As
not all probabilities of a clinical event were available for each
country, we also relied on data from countries in the same region.
For instance, we used data on influenza-related clinical visits from
Kenya [24] for Agincourt and data on hospitalizations and mortal-
ity from Thailand [25] for Thai Nguyen.2.4. Economic analysis
2.4.1. Costs
In our health economic analysis, a societal perspective was
taken, including health care costs as well as costs due to productiv-
ity losses. Healthcare costs included clinic visits with concomitant
drug prescriptions, hospital admissions, vaccines and their delivery
costs, while non-health care costs included productivity losses due
to lost work days (Supplementary methods Table S6). All costs
were expressed in International dollars (I$) and transformed to
the base-year of 2013 using national consumer price indices [26–
28]. International dollars adjust for differences in purchasing
power, enhancing the comparability of monetary outcomes
between LMICs and high-income countries. As the price of QIV
was not available for the countries examined, we had to make an
assumption. We assumed a price for QIV at 50% higher than the
TIV price, similar to the price premium of QIV over TIV given by
the US CDC [29]. Productivity losses due to influenza illness were
calculated by multiplying the number of work days lost by average
daily earnings in the community and applying the friction methods
[30]. More details on conversion rates and cost inputs are pre-
sented in the supplementary material.
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Fig. 2. Relative proportions of influenza A viruses and influenza B viruses stratified by matched and mismatched lineage (See Supplementary methods Table S4 for more
details) by influenza season as used in the model. Split of influenza B by lineage in Vietnam was based on surveillance data from Thailand.
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Influenza-related QALY losses were quantified by summing up
QALY losses due to influenza illness and premature mortality.
QALY-losses for non-hospitalized and hospitalized case were
obtained from the literature [31,32]. Age-specific QALY losses
due to influenza-related death were based on the national lifeexpectancies [33–35] converted to QALYs using health-related
quality-of-life estimates [36–38]. Notably, HIV+ individuals were
assumed to have a lower life expectancy and health-related quality
of life compared with HIV-uninfected individuals [39]. More details
on QALY-loss inputs are presented in the supplementary material
and Supplementary methods Table S7.
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Total costs and QALY losses of the no-vaccination, TIV and QIV
alternatives were added together over the period 2003 to 2013
and ICER was calculated by dividing the incremental costs by the
incremental QALYs. As the analysis was retrospective and vaccina-
tion occurred seasonally, we did not discount costs or health
effects falling in the same year as vaccination. Future costs (e.g.
lifelong productivity losses) were discounted to present values at
3% annually, while future health effects (e.g. preterm mortality)
were not discounted [40].
2.5. Sensitivity analyses
We performed sensitivity analyses to determine the robustness
of model outcomes and the impact of specific assumptions in both
the simulation model and the combined health outcomes/eco-
nomic analysis model. For each scenario a multivariate probabilis-
tic sensitivity analysis (PSA) was conducted to assess the effect of
parameter uncertainty. 1000 Monte-Carlo samples were created,
with health outcomes and economic parameter values drawn from
predefined distributions. This resulted in 1000 separate outcomes
for total costs and total QALY loss per vaccination strategy. Details
on interval ranges of the included economic parameters can be
found in Supplementary methods Tables S5–S7. Net monetary ben-
efits (NMBs) of each simulation were calculated for the three stud-
ied vaccination strategies (no vaccination, TIV, QIV) using the
equation:
NMB ¼ ðk QALYÞ  Cost
where k is the willingness-to-pay (WTP) threshold. For each simu-
lation it was analyzed which vaccination strategy was the most
cost-effective (i.e. the one with the highest NMB) over a range of
WTP thresholds. Cost-effectiveness acceptability curves (CEACs)
were subsequently designed to present proportions of being the
most cost-effective for each vaccination strategy. Finally, a univari-
ate sensitivity analysis on the price difference between QIV and TIV
was performed, by varying the price premium of QIV over TIV
between 0% (QIV price equal to TIV price) to 100% over TIV (QIV
price double of TIV price).3. Results
3.1. Clinical outcomes
The clinical impact under the three alternatives of no-
vaccination, TIV, and QIV is shown in Table 2 for SARs of 5% and
10%. Assuming a SAR of 5%, introduction of vaccination with TIV
was found to reduce the incidence of symptomatic influenza in
each community by 47.3–49.2%. These reductions were found to
be similar across all age-groups (see supplementary results
Figs. S1 and S2). Vaccination led to reductions in clinical visits, hos-
pitalizations and deaths in the range 48.2–59.4% (Table 2). In Agin-
court SA, the additional benefit of QIV over TIV was estimated to
give a 12.1% reduction of symptomatic influenza and a 17.0%
reduction of influenza-related mortality. In Thai Nguyen, the
impact of QIV over TIV was estimated highest (22.5% reduction
of symptomatic influenza and 27.6% reduction of influenza-
related mortality) and in Albany lowest (1.2% reduction of symp-
tomatic influenza and 2.3% of influenza-related mortality). Under
the 10% SAR assumption scenario the additional benefit of QIV over
TIV was estimated to be 9.5% for symptomatic influenza and 14.0%
for influenza-related mortality in Agincourt; 8.9% for symptomatic
influenza and 14.5% for influenza-related mortality in Thai
Nguyen; and 2.0% for symptomatic influenza and 3.3% for
influenza-related mortality in Albany.3.2. Cost-effectiveness outcomes
Table 3 shows the effect of TIV and QIV on total influenza-
related costs and QALY losses per person in each community over
the period 2003–2013. Assuming a SAR of 5%, the ICER of TIV ver-
sus no vaccination was 1803/QALY gained in Agincourt, I$1064/
QALY in Thai Nguyen and I$907/QALY in Albany. Increasing the
SAR to 10% resulted in lower ICERs or even cost-savings (for
instance, vaccination with TIV was estimated cost-saving as com-
pared with no vaccination). When QIV was compared with TIV,
the ICER was estimated at I$4183/QALY in Agincourt, I$1505/QALY
in Thai Nguyen and I$82,669/QALY in Albany using a SAR of 5%.
Assuming a SAR of 10%, the ICER decreased to I$1364/QALY in
Agincourt, I$745/QALY in Thai Nguyen and I$28,419/QALY gained
in Albany. More detailed results on the impact of vaccination on
costs and QALY losses are presented in supplementary results
Table S1 (5% SAR) and Table S2 (10% SAR). In Agincourt, highest
QALY gains due to influenza vaccination were found, but least pro-
ductivity losses were saved. In Albany, vaccination prevented rela-
tively more healthcare costs and productivity losses.3.3. Sensitivity analyses
After using a PSA of 1000 Monte-Carlo samples, CEACs are pre-
sented in Fig. 3. These graphs show for each vaccination alternative
the chance of being the most cost-effective over a range of WTP
thresholds. Corresponding cost-effectiveness planes are shown in
supplementary results Fig. S3. At a SAR of 5%, QIV had a >90% prob-
ability of being the most cost-effective alternative when the WTP
threshold was above I$5200/QALY in Agincourt, I$2150/QALY in
Thai Nguyen and I$220,000/QALY in Albany. The high WTP thresh-
old in Albany can be explained by the small impact that was mod-
elled for QIV as compared with TIV, resulting in more uncertainty.
When a SAR of 10% was used, QIV had a >90% probability of being
the most cost-effective alternative at a WTP threshold to I$1950/
QALY, I$880/QALY and I$15,500/QALY for Agincourt, Thai Nguyen
and Albany, respectively. A univariate sensitivity analysis of the
vaccine price of QIV versus TIV is shown in Fig. 4. Overall, the price
premium of QIV over TIV had a significant impact on cost-
effectiveness results. With a SAR of 5%, the price premium of QIV
should be lower than I$0.31 in Agincourt, I$0.67 in Thai Nguyen
and I$0.16 in Albany to result in cost-saving ICERs. When a SAR
of 10% was assumed, this price premium was allowed to increase
to I$0.73 in Agincourt, I$1.05 in Thai Nguyen and I$1.26 in Albany.4. Discussion
In this study the cost-effectiveness of influenza vaccination
with TIV and QIV was modelled in communities in South Africa
(Agincourt), Vietnam (Thai Nguyen) and Australia (Albany), having
different demographics, economic status, health care resources,
influenza epidemiology and HIV prevalence. We found that cost-
effectiveness of QIV as compared with TIV differed significantly
between countries, being the highest in Albany and lowest in Thai
Nguyen. This difference was explained by greater influenza B co-
circulation and vaccine mismatches in South Africa and Vietnam
during the period 2003–2013 as compared to Australia. Highest
QALY gains due to influenza vaccination were found in Agincourt,
mainly due to a higher risk of influenza-related death in the HIV-
infected population. In Albany, vaccination prevented more health-
care costs and productivity losses due to relatively higher hospital
costs and daily wages. Sensitivity analyses demonstrated that the
SAR and the price of QIV had a high impact on the ICER.
When a no-vaccination SAR of 10% was assumed the propor-
tional reductions in SAR were lower than for the 5% scenario across
Table 2
Impact of vaccination with trivalent influenza vaccine and quadrivalent influenza vaccine on the incidence of symptomatic influenza cases, clinic visits, hospitalizations and
deaths in the communities Agincourt (South Africa), Thai Nguyen (Vietnam) and Albany (Australia) over the period 2003–2013. NV: No vaccination, PY: Person years, QIV:
Quadrivalent influenza vaccine, SAR: Symptomatic attack rate, TIV: Trivalent influenza vaccine.
Community/vaccine alternativea Symptomatic attack
rate (%) per year
(reductiona)
Clinical visit rate per
100,000 PY
(reductiona)
Hospitalization rate
per 100,000 PY
(reductiona)
Mortality rate per
100,000 PY
(reductiona)
5% SAR
Agincourt (SA)
NV 5.0 607 26.0 4.07
TIV 2.6 (47.3%) 279 (54.1%) 11.5 (55.7%) 1.83 (55.1%)
QIV 2.3 (12.1%) 232 (16.7%) 9.5 (17.9%) 1.52 (17.0%)
Thai Nguyen (VN)
NV 5.0 389 43.5 2.01
TIV 2.5 (49.2%) 178 (54.4%) 19.5 (55.2%) 0.88 (56.5%)
QIV 2.0 (22.5%) 130 (26.6%) 14.2 (27.2%) 0.64 (27.6%)
Albany (AUS)
NV 4.9 1093 33.9 1.60
TIV 2.6 (47.6%) 565 (48.3%) 14.7 (56.8%) 0.65 (59.4%)
QIV 2.5 (1.2%) 558 (1.3%) 14.3 (2.3%) 0.63 (2.3%)
10% SAR
Agincourt (SA)
NV 10.1 1252 54.4 8.54
TIV 7.2 (28.6%) 767 (38.7%) 32.0 (41.2%) 5.11 (40.1%)
QIV 6.5 (9.5%) 664 (13.4%) 27.4 (14.4%) 4.40 (14.0%)
Thai Nguyen (VN)
NV 10.0 790 88.7 4.41
TIV 7.6 (24.1%) 532 (32.6%) 58.7 (33.9%) 2.79 (36.7%)
QIV 6.9 (8.9%) 462 (13.1%) 50.6 (13.8%) 2.38 (14.5%)
Albany (AUS)
NV 9.9 2259 73.9 3.78
TIV 7.5 (24.7%) 1680 (25.6%) 45.8 (38.1%) 2.17 (42.7%)
QIV 7.3 (2.0%) 1645 (2.1%) 44.3 (3.3%) 2.10 (3.3%)
a TIV versus NV, and QIV versus TIV.
Table 3
Economic impact, health impact and cost-effectiveness of trivalent influenza vaccine and quadrivalent influenza vaccine in the communities Agincourt (South Africa), Thai
Nguyen (Vietnam) and Albany (Australia) over the period 2003–2013.
Outcome (per person) NV TIV QIV TIV-NV QIV-TIV
5% SAR
Agincourt (SA)
Total societal (I$) 6.90 19.27 23.25 12.36 3.98
Total QALYs lost 0.01294 0.00609 0.00513 0.00686 0.00095
ICER (I$/QALY) 1803 4183
Thai Nguyen (VN)
Total societal (I$) 9.35 13.61 14.98 4.26 1.37
Total QALYs lost 0.00782 0.00381 0.00290 0.00401 0.00091
ICER (I$/QALY) 1064 1505
Albany (Aus)
Total societal (I$) 44.04 46.68 50.14 2.64 3.46
Total QALYs lost 0.00573 0.00282 0.00278 0.00291 0.00004
ICER (I$/QALY) 907 80,966
10% SAR
Agincourt (SA)
Total societal (I$) 14.56 25.05 28.34 10.49 3.29
Total QALYs lost 0.02680 0.01688 0.01475 0.00992 0.00213
ICER (I$/QALY) 1057 1546
Thai Nguyen (VN)
Total societal (I$) 20.38 23.12 23.87 2.74 0.75
Total QALYs lost 0.01603 0.01159 0.01039 0.00444 0.00120
ICER (I$/QALY) 617 620
Albany (Aus)
Total societal (I$) 98.29 93.31 94.95 4.99 1.64
Total QALYs lost 0.01210 0.00847 0.00828 0.00363 0.00020
ICER (I$/QALY) CS 8379
CS: Cost-saving, HCP: Healthcare payer’s perspective, NV: No vaccination, QIV: Quadrivalent influenza vaccine, SAR: Symptomatic attack rate, TIV: Trivalent influenza vaccine.
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Fig. 3. Cost-effectiveness acceptability curves of implementing influenza vaccination with trivalent influenza vaccine and quadrivalent influenza vaccine in the communities
Agincourt (South Africa), Thai Nguyen (Vietnam) and Albany (Australia) over the period 2003–2011, assuming a symptomatic attack rate of 5% (A–C) and 10% (D–F). Results
are based on a probabilistic sensitivity analysis with 1000 simulations. I$: International dollar, NV: No vaccination, QIV: Quadrivalent influenza vaccine, SAR: Symptomatic
attack rate, TIV: Trivalent influenza vaccine, WTP: Willingness-to-pay.
P.T. de Boer et al. / Vaccine 36 (2018) 997–1007 1003all communities, and consequently proportional reductions in clin-
ical visits, hospitalization and mortality were also lower. This is
expected since influenza is more transmissible (i.e. has a higher
R0) in the higher attack rate scenario, which makes all interven-
tions proportionally less effective. This occurred particularly in
the Thai Nguyen model where coverage among young children,
who are disproportionally responsible for onward transmission,was higher than in other communities (see supplementary results
for more explanation). Note however that while the proportional
reductions are lower in the 10% SAR scenario compared to the 5%
scenario, the absolute number of cases prevented is higher. Increase
of the SAR from 5% to 10% improved the cost-effectiveness,
explained by the increase of the absolute number of clinical events
prevented using the same quantity of vaccine.
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Fig. 4. Univariate sensitivity analysis of the price premium of QIV over TIV when a SAR of 5% (A) and 10% (B) was assumed. 0% price premium means that the QIV price is
equal to the TIV price, while 100% price premium means that the QIV price is double of the TIV price. Aus: Australia, ICER: Incremental cost-effectiveness ratio, I$:
International$, QALY: Quality-adjusted life year, QIV: Quadrivalent influenza vaccine, SA: South Africa, SAR: Symptomatic attack rate, TIV: Trivalent influenza vaccine, VN:
Vietnam.
1004 P.T. de Boer et al. / Vaccine 36 (2018) 997–1007To decide whether influenza vaccination is cost-effective and, if
decided yes, whether this should be TIV or QIV, depends on the
country, influenza epidemiology and the countries’ WTP threshold.
For none of the countries involved in this analysis an official cost-
effectiveness threshold is available. For South Africa and Vietnam,
however, a previously estimated threshold for LMICs in general of I
$1045/QALY might be used [41], while a previous study in Aus-
tralia used a threshold of I$32,900 (=Aus$50,000)/QALY [42]. Then,
TIV would be cost-effective in Vietnam and Australia, while for
South-Africa this depends on the attack rate. QIV would only be
cost-effective when a high SAR of 10% was assumed. For Vietnam,
also an official threshold of Thailand might be used, which has
been estimated at I$8100 (=100,000 Thai Baht)/QALY [43]. In that
case, QIV would be cost-effective independent of influenza attack
rate assumptions.
However, a review of the role of cost-effectiveness on introduc-
ing human papillomavirus and rotavirus vaccination in LMICs has
shown that budgetary impact is often deemed more important
for implementing a vaccination program than cost-effectiveness
[44]. Extrapolating the annual budget impact of TIV and QIV to a
national scale in South Africa, the costs of TIV and QIV would be
I$59 million and I$76, respectively, being 0.14% and 0.18% of the
national healthcare budget as estimated by the WHO [45–47]. His-
toric case studies of implemented vaccines for children in South
Africa showed that vaccine costs of pneumococcal vaccination
and rotavirus vaccination were estimated at IS$66 million and IS
$22 million, respectively, while the ICERs ranged between US
$523–1347/QALY [48]. Although the annual budget impact and
cost-effectiveness of influenza vaccination with TIV is still in line
with for instance pneumococcal vaccination (I$1803/QALY), the
ICER we estimated for QIV is significantly higher (I$4183/QALY).
For Vietnam, nationwide vaccination costs would be estimated at
I$63 for TIV and I$79 million for QIV, being 0.34% and 0.43% of
the healthcare budget. Although currently no vaccines have been
implemented structurally, cost-effectiveness analyses of rotavirus
and hepatitis B for children were estimated at I$556/QALY and I
$4/QALY, respectively [49,50]. This could imply that in Vietnam
other non-implemented vaccines might be of higher priority than
influenza vaccination with TIV (I$1.064/QALY) or QIV (I$1505/QALY). It should be noted, however, that influenza requires annual
vaccination, while pneumococcal and rotavirus vaccination confer
longer-term immunity.
To date, the cost-effectiveness of QIV has been shown to be
favorable in several high-income countries [7]. One other study
also assessed the public health and economic impact of QIV versus
TIV in Australia [51]. Excluding vaccination costs, they found that
QIV would result in $I30.6 million (AUS$46.5 million) of savings
to the society between 2002–2013. When we would extrapolate
our results to the whole Australian population, we found savings
of I$6.5 million over a similar period. This difference can be primar-
ily explained by that in our analysis we used approximately three
times lower probabilities of consulting a GP or being hospitalized
due to influenza disease. Other differences were that we used a
dynamic model instead of a static model, a lower coverage rate
(15% vs. 17.5%) and lower hospitalization costs for the elderly
population.
This study has its limitations. The annual attack rate of symp-
tomatic influenza was kept constant at 5% (and 10%) over the 11
years in all three regions, whereas influenza incidence varies per
year and per region. Furthermore, influenza peaks differently
country-by-country, for example southern Vietnam has a tropical
climate with year-round circulation [52], while our model of Thai
Nguyen assumed a winter influenza season. This complicates the
timing of vaccination and may affect vaccine protection, enhancing
the risk of a vaccine mismatch or waning of the vaccine-induced
protection. We used data from Thailand for Vietnam to partition
influenza B between Victoria and Yamagata lineages, as data for
Vietnam was absent. We chose Thailand because it is located in
the same influenza transmission zone as considered by the WHO
Global Influenza Surveillance and Response System [53]. Moreover,
online available influenza laboratory data from WHO’s Flunet
showed a comparable partition of influenza A/H1N1 and A/H1N3
over the period 2006–2013 for both countries (data prior 2006
was not available for Vietnam here) [54]. In Thailand, A/H3N2 con-
tributed to 44% of the total influenza A positive samples, while this
was 47% in Vietnam.
We did not apply cross-protection of TIV to the non-matched B
lineage in our study. However, recent evidence suggests that such a
P.T. de Boer et al. / Vaccine 36 (2018) 997–1007 1005cross-protection exists, that might reach up to 60–70% of the effi-
cacy of the matched influenza strain [55,56]. Including cross-
protection in the analysis would increase the estimated ICERs of
QIV as compared with TIV, as the relative impact of QIV over TIV
is diminished. We assumed the northern hemisphere composition
of TIV for Vietnam in our analysis. Vietnam has a relatively long
latitudinal span, stretching up far above the equator, where also
the community of Thai Nguyen is located. Moreover, it covers tro-
pic and subtropical areas where the concept of hemispheres may
not directly be applied [57]. Although the government eventually
decides whether the northern or southern hemisphere vaccine is
to be used and despite the limitation on the applicability of the
hemisphere concept in a country like Vietnam, the WHO recently
recommended the southern hemisphere vaccine for tropical Asian
countries including the whole of Vietnam [58]. In supplementary
methods Table S2, the B-strains of northern TIV (see Vietnam)
and southern TIV (see South Africa and Australia) are presented
by season, as well as the contribution of both B-lineages to influ-
enza circulation. It shows that the B-strain included in TIV only dif-
fered between the northern and southern hemisphere vaccine
during the seasons 2006 and 2008. Co-circulation of both B-
lineages occurred in these two seasons, however, the southern
hemisphere TIV matched the B-lineage that contributed highest
to influenza circulation better than the northern hemisphere TIV
(18.3% vs. 15.0% in 2006 and 25.0% vs. 16.7% in 2008). This would
result in a slightly lower impact of QIV in Vietnam and a slight
worsening of the cost-effectiveness, without changing our overall
conclusions. Finally, the vaccine efficacy was assumed to be similar
between HIV-infected and HIV-uninfected individuals, which
might be regarded as a simplification as this is still uncertain for
HIV-adults with low CD4 cell count [59].
With regard to clinical and health-economic outcomes, we used
hospitalization and mortality incidences that were based on pneu-
monia and influenza diagnoses only, while influenza is also associ-
ated with other respiratory as well as cardiorespiratory
complications [60]. This reflects a conservative approach, as the
prevented number of hospitalizations and deaths might be higher.
We ignored possible side-effects of the influenza vaccine, although
serious adverse outcomes are rare and the influenza vaccine is gen-
erally regarded as safe, including in HIV-infected individuals [61].
We limited costs in our analysis to direct medical costs and pro-
ductivity losses due to work absenteeism. Costs not involved in
our analysis include, for instance, transport costs, over-the-
counter medication/traditional medicine, and productivity losses
due to influenza-related presenteeism. Finally, the results of the
community models cannot be directly translated to a national set-
ting. For example, the income level and access to healthcare differs
considerably within a country, especially in SA.
Our use of community-specific individual based simulation
models can be considered a major strength of this analysis. Use
of such dynamic systems for cost-effectiveness analyses in infec-
tious diseases interventions is nowadays considered as the pre-
ferred approach [62]. Furthermore, experience with previously
developed community-based models has demonstrated that com-
munity characteristics, such as household size, co-morbidities
and population age structure, strongly influence influenza spread
and the effectiveness of potential influenza mitigation measures
[63]. This illustrates that prevalence of co-morbidities that increase
the risk of severe influenza-related complications, such as HIV for
the Agincourt region, should ideally be evaluated in the context
of a specific community model that represents the target country
or target population within a country. A further strength of our
analysis was the predominant use of data on clinical event proba-
bilities and resulting costs based on country or region specific data
sources.For future research we encourage cost-effectiveness studies to
include other groups at higher risk of influenza illness and its com-
plications recommended by WHO such as children and pregnant
women. For instance, children are generally known as key trans-
mitters of influenza and targeting them could be indirectly effec-
tive in protecting vulnerable populations, the elderly and people
with medical conditions, against influenza disease [64]. Vaccina-
tion of pregnant women has been urged as a priority by the
WHO [65] and performing cost-effectiveness studies for these
target-groups might inform decision makers which target-groups
should be prioritized when distributing vaccines over the
population.5. Conclusion
Our study showed that the cost-effectiveness of vaccination
with TIV and QIV varies by country and is dependent on influenza
epidemiology, vaccine price, willingness-to-pay thresholds and
budgetary impact. Given our assumptions on WTP-threshold and
vaccine price, we found that vaccinating the most vulnerable pop-
ulations, being HIV-infected before elderly and young children,
with TIV was cost-effective in communities in Vietnam and Aus-
tralia during the period 2003–2013. In the South African commu-
nity, however, the cost-effectiveness of TIV was dependent on
the assumed attack rate. QIV was cost-effective in all three com-
munities when a high attack rate was assumed. We note that our
cost-effectiveness estimates do not automatically apply to differ-
ent settings/target groups with different vaccination coverages.
Also, our study is based on historic data, which does not necessar-
ily reflect future influenza circulation. Obviously, our interpreta-
tion should be considered next to the general context for
influenza vaccination in which the notion always exists that world-
wide coverage of vaccination is thought to increase irrespective of
the specific vaccine applied, i.e. be it QIV or TIV.Declaration of interest
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